Sirolimus eluting coronary stent - BIOTRONIK

Drug Profile

Sirolimus eluting coronary stent - BIOTRONIK

Alternative Names: Orsiro hybrid drug eluting coronary stent - BIOTRONIK

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIOTRONIK
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis

Most Recent Events

  • 28 Aug 2017 Efficacy data from the phase III BIOFLOW-V trial in Coronary artery restenosis presented at the Annual Congress of the European Society of Cardiology 2017 (ESC-Card-2017)
  • 14 Apr 2017 Biotronik initiates enrolment in a phase III trial for Coronary artery restenosis (Prevention) in Russia (NCT02247492)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top